The Ensuring Pathways to Innovative Cures Act would extend the time Medicare can negotiate and set prices for small molecule ...
Scientists are diving into the deep sea to study one of the universe’s biggest mysteries—quantum gravity. Using KM3NeT, a ...
Charles Schwab Investment Management Inc. boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by ...
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price objective raised by JPMorgan Chase & Co. from $39.00 to $41.00 in a research note released on Thursday morning,Benzinga reports.
Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.